182 related articles for article (PubMed ID: 31239516)
21. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
22. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
Uehara H; Takahashi T; Izumi K
Int J Oncol; 2013 Aug; 43(2):365-74. PubMed ID: 23708710
[TBL] [Abstract][Full Text] [Related]
23. Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
Barakat DJ; Suresh R; Barberi T; Pienta KJ; Simons BW; Friedman AD
PLoS One; 2018; 13(1):e0191188. PubMed ID: 29324844
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway.
Chang YL; Zhou PJ; Wei L; Li W; Ji Z; Fang YX; Gao WQ
Oncotarget; 2015 Sep; 6(27):24017-31. PubMed ID: 26172296
[TBL] [Abstract][Full Text] [Related]
25. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
Al Nakouzi N; Bawa O; Le Pape A; Lerondel S; Gaudin C; Opolon P; Gonin P; Fizazi K; Chauchereau A
Neoplasia; 2012 May; 14(5):376-87. PubMed ID: 22745584
[TBL] [Abstract][Full Text] [Related]
26. [Role and action mechanisms of FZD5 in prostate cancer bone metastasis in mice].
Zhang X; Mo QW
Zhonghua Nan Ke Xue; 2016 Feb; 22(2):128-32. PubMed ID: 26939396
[TBL] [Abstract][Full Text] [Related]
27. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
[TBL] [Abstract][Full Text] [Related]
28. Krüppel-like factor 4 negatively regulates β-catenin expression and inhibits the proliferation, invasion and metastasis of gastric cancer.
Zhang N; Zhang J; Shuai L; Zha L; He M; Huang Z; Wang Z
Int J Oncol; 2012 Jun; 40(6):2038-48. PubMed ID: 22407433
[TBL] [Abstract][Full Text] [Related]
29. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
30. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
Ganguly SS; Hostetter G; Tang L; Frank SB; Saboda K; Mehra R; Wang L; Li X; Keller ET; Miranti CK
Oncogene; 2020 Jan; 39(1):204-218. PubMed ID: 31467432
[TBL] [Abstract][Full Text] [Related]
31. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.
Bae KM; Su Z; Frye C; McClellan S; Allan RW; Andrejewski JT; Kelley V; Jorgensen M; Steindler DA; Vieweg J; Siemann DW
J Urol; 2010 May; 183(5):2045-53. PubMed ID: 20303530
[TBL] [Abstract][Full Text] [Related]
32. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition.
Liu YN; Abou-Kheir W; Yin JJ; Fang L; Hynes P; Casey O; Hu D; Wan Y; Seng V; Sheppard-Tillman H; Martin P; Kelly K
Mol Cell Biol; 2012 Mar; 32(5):941-53. PubMed ID: 22203039
[TBL] [Abstract][Full Text] [Related]
33. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
[TBL] [Abstract][Full Text] [Related]
34. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
35. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
[TBL] [Abstract][Full Text] [Related]
36. Kruppel-like factor 4 is a novel mediator of selenium in growth inhibition.
Liu S; Zhang H; Zhu L; Zhao L; Dong Y
Mol Cancer Res; 2008 Feb; 6(2):306-13. PubMed ID: 18314491
[TBL] [Abstract][Full Text] [Related]
37. Krüppel-like factor 4 regulates membranous and endochondral ossification.
Michikami I; Fukushi T; Tanaka M; Egusa H; Maeda Y; Ooshima T; Wakisaka S; Abe M
Exp Cell Res; 2012 Feb; 318(4):311-25. PubMed ID: 22206865
[TBL] [Abstract][Full Text] [Related]
38. The Janus-faced roles of Krüppel-like factor 4 in oral squamous cell carcinoma cells.
Li W; Liu M; Su Y; Zhou X; Liu Y; Zhang X
Oncotarget; 2015 Dec; 6(42):44480-94. PubMed ID: 26517087
[TBL] [Abstract][Full Text] [Related]
39. Attenuation of krüppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma.
Song E; Ma X; Li H; Zhang P; Ni D; Chen W; Gao Y; Fan Y; Pang H; Shi T; Ding Q; Wang B; Zhang Y; Zhang X
PLoS One; 2013; 8(7):e67758. PubMed ID: 23861801
[TBL] [Abstract][Full Text] [Related]
40. SOST Inhibits Prostate Cancer Invasion.
Hudson BD; Hum NR; Thomas CB; Kohlgruber A; Sebastian A; Collette NM; Coleman MA; Christiansen BA; Loots GG
PLoS One; 2015; 10(11):e0142058. PubMed ID: 26545120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
